CO5160292A1 - Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales - Google Patents

Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales

Info

Publication number
CO5160292A1
CO5160292A1 CO00023495A CO00023495A CO5160292A1 CO 5160292 A1 CO5160292 A1 CO 5160292A1 CO 00023495 A CO00023495 A CO 00023495A CO 00023495 A CO00023495 A CO 00023495A CO 5160292 A1 CO5160292 A1 CO 5160292A1
Authority
CO
Colombia
Prior art keywords
imidazolo
treatment
pharmaceutical composition
viral
tienil
Prior art date
Application number
CO00023495A
Other languages
English (en)
Inventor
Camden James Berger
Joseph Herman Gardner
David Thomas Stanton
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of CO5160292A1 publication Critical patent/CO5160292A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica que comprende de 0.5 a 95% en peso de un derivado de 2-tienil-imidazolo [4,5]piridina basado en el peso total de dosificación y que tiene la fórmula:<EMI FILE="00023495_1" ID="1" IMF=JPEG >en donde n es de 1 a 4, R se selecciona del grupo que consiste de hidrógeno, alquilo que tiene de u 1 a 7 átomos de carbono, cloro, bromo, fluoro, oxicloro, hidroxi, sulfhidrilo, alcoxi que tiene la fórmula - O(CH2)yCH3 en donde y es de 0 a 6, las prodrogas de ésta y las sales farmacéuticamente aceptables de ésta, en donde la composición antes mencionada usada en el tratamiento de infecciones vírales.
CO00023495A 1999-03-31 2000-03-31 Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales CO5160292A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189299A 1999-03-31 1999-03-31

Publications (1)

Publication Number Publication Date
CO5160292A1 true CO5160292A1 (es) 2002-05-30

Family

ID=23079205

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00023495A CO5160292A1 (es) 1999-03-31 2000-03-31 Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales

Country Status (11)

Country Link
US (2) US6194430B1 (es)
EP (1) EP1165077B1 (es)
JP (1) JP2002540151A (es)
AR (1) AR018706A1 (es)
AT (1) ATE298569T1 (es)
AU (1) AU763431B2 (es)
CA (1) CA2365495C (es)
CO (1) CO5160292A1 (es)
DE (1) DE60021065T2 (es)
NZ (1) NZ514558A (es)
WO (1) WO2000057870A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969367B2 (en) * 2000-02-02 2005-11-29 Xepmed, Inc. Extracorporeal pathogen reduction system
US6613507B1 (en) 2000-03-21 2003-09-02 Yu-an Chang Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
IL151475A0 (en) 2000-03-30 2003-04-10 Bristol Myers Squibb Co Beadlets containing stavudine
AU7438301A (en) * 2000-06-23 2002-01-02 Kotze, Gavin Salomon The use of synthetic, non-hormonal 21-aminosteroids, derivatives, metabolites and precursors thereof in the treatment of viral infections
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
WO2003082273A1 (en) * 2002-03-26 2003-10-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Solubilization of weak bases
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
ES2358730T3 (es) * 2002-07-15 2011-05-13 Board Of Regents, The University Of Texas System Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20080027575A1 (en) * 2006-04-21 2008-01-31 Jones Stevan D Modeling systems for health and beauty consumer goods
CN110294751B (zh) * 2018-03-21 2020-11-20 湖南化工研究院有限公司 具生物活性的咪唑[4,5-b]并吡啶类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
IL37752A (en) 1970-09-21 1974-10-22 Rhone Poulenc Sa Imidazo(4,5-b)pyridine-2-carbamic acid derivatives,processes for their preparation and pharmaceutical and veterinary compositions containing the same
AT379395B (de) * 1983-11-14 1985-12-27 Laevosan Gmbh & Co Kg Verfahren zur herstellung von neuen 2(2-thienyl)-imidazo (4,5-b) pyridin-derivaten und deren pharmazeutisch vertraeglichen saeureadditionssalzen
DE3722992A1 (de) * 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
US20030232851A1 (en) 2003-12-18
AU4048900A (en) 2000-10-16
WO2000057870A2 (en) 2000-10-05
AU763431B2 (en) 2003-07-24
EP1165077B1 (en) 2005-06-29
DE60021065D1 (de) 2005-08-04
DE60021065T2 (de) 2006-06-01
CA2365495C (en) 2007-01-02
US6194430B1 (en) 2001-02-27
EP1165077A2 (en) 2002-01-02
JP2002540151A (ja) 2002-11-26
AR018706A1 (es) 2001-11-28
WO2000057870A3 (en) 2001-03-08
CA2365495A1 (en) 2000-10-05
ATE298569T1 (de) 2005-07-15
NZ514558A (en) 2004-02-27

Similar Documents

Publication Publication Date Title
CO5160292A1 (es) Composicion farmaceutica que contiene derivados de 2-tienil- imidazolo[4,5]piridina, util para el tratamiento de infeccio nes virales
TR200003383T2 (tr) HIV ve diğer virüs enfeksiyonlarının tedavisine yönelik bileşimler.
CO5160294A1 (es) Composicion farmaceutica que inhibe o detiene el crecimiento de virus en animales particularmente mamiferos sarrollo de virus en animales y composiciones farmaceuticas que los contienen
RU96115142A (ru) Производные 5-(2-имидазолиниламино)бензимидазола, их получение и применение в качестве агонистов альфа-2-адреноцепторов
DE69415445D1 (de) Zytotoxische Stilben-Derivate und diese enthaltende pharmazeutische Zusammensetzungen
HUP0300850A2 (hu) Gyűrűs béta-aminosav-származékok mint mátrix metalloproteázok és a TNF-alfa inhibitorok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EA200500846A1 (ru) Замещенные арилтиомочевины и родственные соединения; ингибиторы вирусной репликации
EA200000731A1 (ru) Альфа-аминоамидные производные, полезные в качестве анальгетических агентов
DK1487829T3 (da) Thiadizolylpiperazinderivater, der er nyttige til behandling eller forebyggelse af smerte
ATE404539T1 (de) Kondensierte pyridinderivate
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
EA200101194A1 (ru) Производные 4,5,6,7-тетрагидроиндазола в качестве противоопухолевых средств
HUP0105414A2 (hu) Pirrolo-izokinolin-, azepino- és diazepino-indol-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
LU92033I2 (fr) Plerixafor et ses dérivés pharmaceutiquement acceptables (MOZOBIL®)
KR930703303A (ko) 1, 4-벤조티아제핀 유도체
KR900003170A (ko) 신규 화합물
PE20010541A1 (es) Uso de una composicion de benzimidazol para tratar el cancer
AR003137A1 (es) Una composicion farmaceutica para tratar la leucemia
CO5080752A1 (es) INHIBIDORES DEL FACTOR DE TRANSCRIPCION NF-kB
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
KR900701716A (ko) 치환된 β-디 케톤류
KR910004609A (ko) 아미노케톤 유도체 및 그의 용도
KR930017581A (ko) 혈소판 응집 억제용 약제학적 조성물
TR200002831A2 (tr) Kinolin-4-İl türevleri I
ES2088567T3 (es) Empleo de derivados de la 2-iminotioazolidin-4-ona como nuevos productos activos para medicamentos.